Insurance
Marketing
Pharmaceuticals
Technology/Innovation
Regulatory
Community
Johnson & Johnson
Press release submission
| May 21, 2021
RYBREVANT™ (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Press release submission
| Dec 20, 2019
JOHNSON & JOHNSON: Acquires TARIS Biomedical with Focus on Transforming the Treatment of Bladder Cancer
Press release submission
| Jun 14, 2019
JOHNSON & JOHNSON: Janssen reports top-line Phase 3 results for TREMFYA® (guselkumab) in adults with active psoriatic arthritis
Trending
+
Marketing
Patient Daily
| Apr 22, 2024
Medfluence Senior Director of Business Development on healthcare marketing: 'Patient experience matters more than ever in patient acquisition'
+
Pharmaceuticals
Patient Daily
| Apr 24, 2024
Researchers Look for Long-Term Hearing Loss Treatments
+
Pharmaceuticals
Patient Daily
| Apr 24, 2024
American Lung Association Report: Utah Receives Poor Grades for Ozone and Particle Pollution
+
Pharmaceuticals
Patient Daily
| Apr 23, 2024
Kentucky Father with Terminal Lung Cancer Now Cancer-Free After Innovative Double-Lung Transplant at Northwestern Medicine